about
Recent advances in the field of anti-cancer immunotherapyOpportunities for functional selectivity in GPCR antibodiesFunctional Connectivity Disruption in Neonates with Prenatal Marijuana ExposureAllosteric control of ligand-binding affinity using engineered conformation-specific effector proteinsStructural snapshots reveal distinct mechanisms of procaspase-3 and -7 activationAn allosteric switch for pro-HGF/Met signaling using zymogen activator peptidesSelection of recombinant anti-SH3 domain antibodies by high-throughput phage display.Synthetic Antibodies Inhibit Bcl-2-associated X Protein (BAX) through Blockade of the N-terminal Activation Site.Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug DiscoveryCross-domain inhibition of TACE ectodomainThe importance of being tyrosine: lessons in molecular recognition from minimalist synthetic binding proteins.Small-molecule activators of a proenzyme.Combinatorial libraries against libraries for selecting neoepitope activation-specific antibodies.Allosteric regulation of protease activity by small molecules.Monobodies and other synthetic binding proteins for expanding protein scienceGeneration of recombinant guinea pig antibody fragments to the human GABAC receptor.Beyond natural antibodies: the power of in vitro display technologies.Inflammatory stimuli regulate caspase substrate profiles.A novel β-loop scaffold of phage-displayed peptides for highly specific affinities.A strategy for phage display selection of functional domain-exchanged immunoglobulin scaffolds with high affinity for glycan targets.Protein binding specificity versus promiscuity.Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7.Generating conformation-specific synthetic antibodies to trap proteins in selected functional statesSide chain requirements for affinity and specificity in D5, an HIV-1 antibody derived from the VH1-69 germline segmentSequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases.The demonstration of αKlotho deficiency in human chronic kidney disease with a novel synthetic antibodyTurning on caspases with genetics and small moleculesRecombinant renewable polyclonal antibodies.Synthetic antibodies and peptides recognizing progressive multifocal leukoencephalopathy-specific point mutations in polyomavirus JC capsid viral protein 1.Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.A High Through-put Platform for Recombinant Antibodies to Folded Proteins.Generating Conformation and Complex-Specific Synthetic Antibodies.Substrate and inhibitor-induced dimerization and cooperativity in caspase-1 but not caspase-3.Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein.Dissecting an allosteric switch in caspase-7 using chemical and mutational probesProtein engineering strategies for the development of viral vaccines and immunotherapeutics.Mechanisms of macromolecular protease inhibitorsAffinity proteomics: the role of specific binding reagents in human proteome analysis.Identification of specific tethered inhibitors for caspase-5.
P2860
Q26775602-C1640C3F-993F-45CF-9507-0734ABF5F2F1Q26859602-3B38CF39-13A7-4952-A990-253F92BBB9D4Q27317300-FC2B3EE5-0888-4A8F-AA11-ECEFC8903EE7Q27667191-45E3DDCC-7641-42D2-92BD-E521497461B0Q27678026-9DB6D04C-F3B3-4768-B720-D86D5155D604Q27690294-F1A81403-9028-4F86-817E-14380C5465C4Q30009128-FCADD053-0F0C-439B-A9C7-9C4175F1509BQ30381337-F06291FD-EF53-4256-8CB6-CCF21DEB6078Q30390894-6E584325-1DE5-44D5-A9DF-B05E26259702Q30499696-B0D8B858-84A1-4F37-B55A-6FF8534A4A8CQ33419652-A8023184-2CB7-426E-905A-D9DD9357D130Q33515227-4FD32281-4FA0-4DFC-84AC-C110B8EE929BQ33544140-CD1396DE-5536-4A72-81C4-36147B6D6813Q33601580-C7D9941F-4DA9-4006-9771-3646C7697BA8Q33604222-BE6FE899-55A6-4CBA-A12B-B2B58183FDF3Q33833260-F753FA99-23D7-4F68-9990-8C67FA36CA1FQ33841864-B6FCB813-F331-4F55-9865-3300FA461309Q33854989-0F71144F-FCAB-4584-84E4-8A9FD685FB98Q33927497-A5D72484-33D3-4AF2-AD67-24B82CBC554BQ34123202-5E7E81C7-566E-41B6-A045-B285DE8EF9EBQ34149308-7C2515AF-668E-4357-B111-2EF45071A985Q34487783-F857A0CF-BC8D-410C-BB64-9DB5F4CD0E46Q34528889-751E43F8-BDF2-4DE7-BA18-AFA769F94917Q34659242-775898EC-E7FF-4B35-A0BF-21CBD2EF893DQ34799960-C7FA8848-4F93-4DA6-AD2E-25D124737EE8Q35022247-E8A349ED-6E51-4F5D-A228-230C96C3372AQ35196956-106EBA0C-832D-4429-B286-6C2615F4E79EQ35531929-0639D69C-796E-42E5-8800-947155E8A55DQ35602977-21523DD3-24E9-4C4B-B7C5-16D2F28190FBQ35765577-4E5707E5-B202-48E7-BEBD-BEC15F480BB8Q35992493-9BB3A0FF-C971-4CE6-B333-00CEDF248664Q36134059-6A44EB26-F6B0-4FAD-8433-4C1E730BABBAQ36296236-5AA6217C-B833-4F5B-B51A-FCAF0F1B1B2BQ36742286-8A85FEA0-F4BF-4EB6-B88E-E2268DF3076EQ36934038-368EC58F-F64C-4371-95A5-FD0EE35F2714Q37377747-B13E27C6-4601-4F9A-9AF2-9A2C242E1BCEQ37625877-A418B3EE-5E56-44F4-9AA9-E73D33C6CA64Q37807358-2DB75452-32CA-40C1-87A0-1140B37F9CB3Q38042457-DBACC660-3DCC-44B5-BB37-6711DFA69EF0Q40836289-100EADC9-F28D-44D5-834D-011CF1902053
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Two-state selection of conformation-specific antibodies
@ast
Two-state selection of conformation-specific antibodies
@en
type
label
Two-state selection of conformation-specific antibodies
@ast
Two-state selection of conformation-specific antibodies
@en
prefLabel
Two-state selection of conformation-specific antibodies
@ast
Two-state selection of conformation-specific antibodies
@en
P2093
P2860
P356
P1476
Two-state selection of conformation-specific antibodies
@en
P2093
James A Wells
Junjun Gao
Sachdev S Sidhu
P2860
P304
P356
10.1073/PNAS.0812952106
P407
P577
2009-02-10T00:00:00Z